Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)
Trial Parameters
Brief Summary
This prospective interventional clinical study evaluates the efficacy and safety of combining systemic chemotherapy followed by ablative stereotactic body radiotherapy (SBRT) as first-line treatment in adult patients with locally advanced, inoperable pancreatic cancer. The study aims to determine the response rate after SBRT delivered following initial chemotherapy, as well as time to disease progression and treatment-related toxicity. Patients receive standard first-line chemotherapy and, in the absence of disease progression, undergo ablative SBRT to the primary tumor, followed by continuation of systemic therapy according to clinical practice. The study is conducted in Slovenia, with patient enrollment expanded to additional participating clinical centers following an approved amendment.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older * Locally advanced, inoperable pancreatic cancer * Treated with first-line systemic chemotherapy followed by stereotactic body radiotherapy (SBRT) at participating centers * Ability to provide written informed consent Exclusion Criteria: * Metastatic pancreatic cancer * Prior systemic therapy for locally advanced pancreatic cancer (one or more previous lines of systemic treatment) * Disease progression after initial chemotherapy prior to SBRT * Any condition that, in the investigator's opinion, would interfere with study participation or evaluation